Oral Presentation The Annual Scientific Meeting of the Endocrine Society of Australia and the Society for Reproductive Biology 2014

Bone effects of endocrine cancer treatment (#175)

Mathis Grossmann 1
  1. University of Melbourne, Austin Health, Heidelberg, VIC, Australia

Hormone sensitive cancers such as prostate cancer and estrogen receptor positive breast cancer respond to sex steroid deprivation. Given the often relatively good prognosis of these common malignancies, adverse bone related effects of endocrine cancer treatment need to be managed proactively to optimize the risk benefit ratio of this treatment. In this symposium talk, I will highlight recent developments in this area, including our research and clinical experience with our dedicated clinics managing endocrine side effects of firstly, androgen deprivation therapy in prostate cancer and secondly of aromatase inhibition in breast cancer.